SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Dr. Jonathan Cheng as Chief Medical Officer. He joined SystImmune from Bristol Myers Squibb, where he served as the Senior Vice President and Therapeutic Area Oncology Head, overseeing late-stage clinical development of the oncology portfolio. Dr. Cheng succeeds Dr. Martin Olivo, who is leaving SystImmune to pursue external opportunities.
SystImmune是一家處于臨床階段的前沿生物制藥公司，專注于開發(fā)用于癌癥治療的新型雙特異性、多特異性抗體及抗體藥物偶聯物（ADCs）。公司今天宣布任命Jonathan Cheng博士為SystImmune新任首席醫(yī)學官。在加入SystImmune之前，Cheng博士在百時美施貴寶擔任高級副總裁兼腫瘤發(fā)展主管，負責管理抗腫瘤管線的臨床后期開發(fā)。通過本次任命，Cheng 博士接替了Martin Olivo 博士，后者為尋求外部發(fā)展機會已離開SystImmune。
“I am excited to welcome Dr. Cheng to our leadership team,” said Jie D’Elia, Ph.D., Chief Ｅxecutive Officer of SystImmune. “His global oncology development expertise and in-depth regulatory knowledge will accelerate our efforts to advance SystImmune’s pipeline and transform patient care. On behalf of the SystImmune team, I want to express our deep appreciation to Dr. Martin Olivo for his dedication and contributions to SystImmune. We wish him well in his future endeavors.”
SystImmune首席執(zhí)行官Jie D'Elia博士表示：“我很高興并歡迎Cheng博士加入我們的領導團隊。他在全球腫瘤藥物開發(fā)領域的專業(yè)沉淀和對行業(yè)監(jiān)管的深刻理解，將加速SystImmune的管線進度，并進一步推動我們對患者治療的變革。我謹代表SystImmune團隊，向Martin Olivo博士對公司的奉獻表示深深的謝意。我們祝愿他在未來一切順利。”
Dr. Yi Zhu, Chairman of SystImmune, stated “Dr. Cheng brings a wealth of expertise and a remarkable track record in oncology drug development, making him an invaluable addition to SystImmune’s Ｅxecutive leadership team.”
SystImmune董事長朱義博士表示：“Cheng博士在腫瘤藥物開發(fā)領域擁有豐富的專業(yè)知識和卓越的業(yè)績，他的加入讓SystImmune領導團隊更加壯大?！?/span>
Dr. Cheng’s career spans both the pharmaceutical industry and academia, where he has consistently demonstrated exceptional leadership and a passion for advancing cancer treatments. Under Dr. Cheng’s leadership, BMS developed and received regulatory approval for multiple important medicines, including Nivolumab, Ipilimumab, Relatlimab, and Repotrectinib. His strategic vision also enhanced BMS’s internal and collaboration portfolio. Previously, Dr. Cheng served as Therapeutic Area Head of Oncology at Merck and led teams in securing approvals for Pembrolizumab and Lenvatinib across multiple oncology indications. Prior to his career in the pharmaceutical industry, Dr. Cheng had a successful academic career at Fox Chase Cancer Center, where he conducted groundbreaking research as the principal investigator in tumor stromal biology, resulting in over 150 original manuscripts and abstracts. Dr. Cheng received a BS from Marquette University and an MD from the University of Minnesota.
Cheng博士的職業(yè)生涯跨越制藥行業(yè)和學術界，在推動癌癥治療方面始終展現了非凡的領導能力和熱情。在他的領導下，BMS開發(fā)并上市了多種重要藥物，包括Nivolumab、Ipilimumab、Relatlimab和Repotrectinib。他的戰(zhàn)略遠見，增強了該公司內部產品線以及合作管線的競爭力。在加入BMS之前，Cheng博士為默沙東腫瘤臨床研究副總裁，并領導團隊取得Pembrolizumab和Lenvatinib在多個腫瘤適應癥的上市獲批。在進入制藥行業(yè)之前，Cheng博士在 Fox Chase 癌癥中心擁有成功的學術生涯。他作為腫瘤基質生物學的首席研究員，進行了開創(chuàng)性的研究，并形成150 多份原始手稿和摘要。Cheng博士獲得馬凱特大學學士學位和明尼蘇達大學醫(yī)學博士學位。
For further information, please contact: info@systimmune.com
如需更多信息，請聯系:info@systimmune.com
About SystImmune
SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has multiple assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development.
關于SystImmune
SystImmune是一家位于華盛頓州雷德蒙德的處于臨床階段的生物制藥公司。該公司專注于利用其成熟的藥物開發(fā)平臺，開發(fā)創(chuàng)新的癌癥治療方法，包括雙特異性、多特異性抗體及抗體藥物偶聯物（ADCs）。SystImmune在實體瘤和血液病領域的多個臨床試驗階段均擁有管線和技術儲備。除了正在進行的臨床試驗外，公司還擁有強大的臨床前管線，包括處于發(fā)現階段或IND階段的潛在癌癥治療藥物，代表著公司在生物制藥開發(fā)領域的領先實力。
